Search

Antibodies to factor XIII have not been previously characterized in detail. An acquired inhibitor to factor XIII, which developed in a patient following thrombectomy for a femoral artery occlusion, has been characterized as to immunoglobulin composition. A highly sensitive monodansylcadaverine assay for factor XIII was employed. The inhibitor was completely neutralized by antisera specific for the γG class, γG1 subclass, and λ light-chain type. Antisera to γG2, γG3, γG4, γA, γM, γD, γE, and k light-chains had no detectable effect. Preparative zone electrophoresis revealed the inhibitor to be in the cathodal portion of the gamma peak, with moderately restricted electrophoretic mobility. The factor XIII inhibitor is thus characterized as a γGl, λ immunoglobulin and resembles other human antibodies to clotting factors that are restricted in immunoglobulin composition.

Every attempt should be made to differentiate tumor simulating hypertrophic gastritis from carcinoma of the stomach clinically or, if necessary, by exploratory laparotomy with biopsy. On the basis of available statistical evidence tumor simulating hypertrophic gastritis is not a proven premalignant lesion. The majority of symptoms in this disease entity will respond to medical management. Therefore, there are only a very few patients in whom gastrectomy is indicated.

n/a